Medical Oncologist
Your treatment timeline
How Long Will You Stay — on Trastuzumab?
The honest answer depends on your cancer stage. For early-stage breast cancer, there is a defined end date. For advanced cancer, treatment continues until a specific stopping rule applies — and knowing those rules makes the uncertainty easier to manage.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
- One year in early-stage cancer — NCCN and ASCO guidance sets one year as the standard adjuvant course for HER2-positive early breast cancer.
- No fixed end in advanced disease — In metastatic cancer, trastuzumab continues as long as it is controlling the disease and your body is tolerating it.
- Your heart decides too — Heart function is monitored throughout. A significant drop may pause or stop treatment regardless of where you are in the course.
- Stopping early is not failure — Completing a shorter course because of a side effect is a clinical decision made to protect you, not a sign the treatment did not work.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
For early-stage HER2-positive breast cancer, NCCN and ASCO guidance recommends one year of trastuzumab. For advanced or metastatic cancer, trastuzumab continues for as long as it controls the disease. The stopping rule differs by stage: a fixed end date for early disease, and a clinical decision based on response and tolerance for advanced disease.
What does a one-year trastuzumab course look like from start to finish?
Before the first infusion
Your team checks your heart's pumping function — called the LVEF — with an echocardiogram or MUGA scan. This is the baseline against which all future readings will be compared.
Starting treatment
Trastuzumab is given as an intravenous infusion, usually every three weeks. In early-stage disease it often runs alongside or after chemotherapy. Each session is day care — you go home the same day.
During treatment
Your heart function is rechecked at intervals throughout the course. If your LVEF drops significantly from your baseline, your team may pause treatment and reassess. Many pauses are temporary.
Reaching the planned end
For early-stage cancer, NCCN and ASCO guidance sets one year as the standard duration. Your last infusion marks the completion of the course. Treatment does not taper — it simply stops.
After the final infusion
Your team will check your heart function once more, typically a few months after finishing. Follow-up visits continue, but the trastuzumab infusions are done.
What makes trastuzumab stop before the full course is done?
The most common reason for stopping early is a significant drop in your heart's pumping function. Trastuzumab can reduce this function in a proportion of patients, and monitoring exists specifically to catch it early.
If your LVEF drops beyond the threshold your team uses, treatment will be paused. Many patients restart after a recovery period and complete the full course.
In metastatic disease the stopping rule is different. Treatment continues until scans or symptoms show the cancer is no longer responding, or until side effects make continuing unsafe.
Being told to stop early is not a sign of failure. It is a decision made from your body's real-time results, and it is made to protect you.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
Which symptoms do I need to report during trastuzumab treatment?
- New breathlessness — especially when lying flat or during mild activity
- Ankle or foot swelling that is new or getting worse
- Chest pain, tightness, or a sense of pressure
- A feeling that your heart is racing or beating irregularly
- Unusual fatigue that does not improve with rest
- Any thought of becoming pregnant — tell your team before you decide anything
What happens to your body when trastuzumab finishes?
Trastuzumab does not need to be tapered. When the course ends, it stops completely. There is no withdrawal effect.
Your heart function usually improves after treatment ends, particularly if your LVEF was affected during the course. A final check confirms this.
For metastatic cancer, your oncologist may discuss switching to a different HER2-targeted medicine if trastuzumab stops controlling the disease. Resistance to trastuzumab is not the end of HER2-directed therapy.
After finishing, any new cardiac symptoms — breathlessness, swelling, palpitations — should still be reported promptly. The monitoring period does not end the day the infusions do.
Explore 75 more Breast Cancer Targeted Medicines topics
Drug Deep Dive: Trastuzumab (Herceptin)
- Adjuvant Trastuzumab: Why Exactly 12 Months After Surgery?
- Diet and Nutrition While on Trastuzumab
- Drug, Food and Supplement Interactions With Trastuzumab
- Fatigue, Chills and Flu-Like Symptoms After a Trastuzumab Infusion
- Fertility, Pregnancy and Contraception on Trastuzumab
- Heart Function and Trastuzumab: Understanding Your ECHO Reports
- Herceptin vs Biosimilar Trastuzumab: Are They Really the Same?
- How Does Trastuzumab Work? The Anti-HER2 Monoclonal Antibody Explained
- How Long Does Trastuzumab Take to Work?
- How Long Will You Stay on Trastuzumab?
- Subcutaneous Trastuzumab vs IV Infusion: Which Suits You Better?
- Tests and Monitoring While You Are on Trastuzumab
- Trastuzumab (Herceptin and biosimilars): The Complete Patient Guide
- Trastuzumab Infusion Day: Premedication, Duration and What to Expect
- Trastuzumab Infusion Reactions: What Happens and How They're Managed
- Trastuzumab Myths: 'It's Chemotherapy' and Other Misunderstandings
- Trastuzumab Price in India: Innovator, Biosimilar and Cost Per Cycle
- Trastuzumab Side Effects: The Complete List and Timeline
- Trastuzumab Success Rate and Survival: An Honest Look at the Numbers
- Trastuzumab With Pertuzumab, Chemotherapy and Hormone Therapy
- Trastuzumab in Elderly Patients and Those With Other Illnesses
- When Trastuzumab Stops Working: Resistance and What Comes Next
- Who Is Eligible for Trastuzumab? HER2-Positive Breast and Gastric Cancer
- Will Insurance or a Government Scheme Pay for Trastuzumab?
- Work, Travel and Daily Life on Trastuzumab
Drug Deep Dive: Palbociclib (Ibrance)
- Diet and Nutrition While on Palbociclib
- Drug, Food and Supplement Interactions With Palbociclib
- Fatigue on Palbociclib: Why It Happens and What Genuinely Helps
- Fertility, Pregnancy and Contraception on Palbociclib
- How Does Palbociclib Work? The CDK4/6 Inhibitor Explained
- How Long Does Palbociclib Take to Work?
- How Long Will You Stay on Palbociclib?
- Low White Cell Count on Palbociclib: Expected, and Rarely Dangerous
- Mouth Sores and Infection Risk on Palbociclib
- Palbociclib (Ibrance, Palbace): The Complete Patient Guide
- Palbociclib Myths: Low Counts, Hair Loss and Stopping Early
- Palbociclib Price in India: Brand, Generic and Monthly Cost
- Palbociclib Side Effects: The Complete List and Timeline
- Palbociclib Success Rate and Survival: An Honest Look at the Numbers
- Palbociclib With Letrozole or Fulvestrant: Understanding Your Combination
- Palbociclib in Early Breast Cancer: Why It Is Not Given After Surgery
- Palbociclib in Elderly Patients and Those With Other Illnesses
- Palbociclib vs Ribociclib vs Abemaciclib: Which CDK4/6 Inhibitor?
- Taking Palbociclib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Palbociclib
- The 21-Days-On, 7-Days-Off Palbociclib Cycle Explained
- When Palbociclib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Palbociclib? Hormone-Receptor-Positive, HER2-Negative Breast Cancer
- Will Insurance or a Government Scheme Pay for Palbociclib?
- Work, Travel and Daily Life on Palbociclib
Drug Deep Dive: Trastuzumab Deruxtecan (Enhertu)
- Diet and Nutrition While on Trastuzumab Deruxtecan
- Drug, Food and Supplement Interactions With Trastuzumab Deruxtecan
- Enhertu Myths: 'It's Just Stronger Herceptin' and Cost Misconceptions
- Enhertu in Breast, Gastric and Lung Cancer: One Drug, Three Diseases
- Fertility, Pregnancy and Contraception on Trastuzumab Deruxtecan
- HER2-Low Breast Cancer: How Enhertu Created an Entirely New Patient Group
- How Does Trastuzumab Deruxtecan Work? The HER2-Directed Antibody-Drug Conjugate Explained
- How Long Does Trastuzumab Deruxtecan Take to Work?
- How Long Will You Stay on Trastuzumab Deruxtecan?
- Interstitial Lung Disease on Enhertu: The Side Effect That Needs Immediate Action
- Low Blood Counts, Hair Loss and Heart Monitoring on Enhertu
- Nausea and Vomiting on Trastuzumab Deruxtecan: Managing a High-Risk ADC
- Tests and Monitoring While You Are on Trastuzumab Deruxtecan
- Trastuzumab Deruxtecan (Enhertu): The Complete Patient Guide
- Trastuzumab Deruxtecan Infusion Day: Premedication, Duration and What to Expect
- Trastuzumab Deruxtecan Price in India: Innovator, Biosimilar and Cost Per Cycle
- Trastuzumab Deruxtecan Side Effects: The Complete List and Timeline
- Trastuzumab Deruxtecan Success Rate and Survival: An Honest Look at the Numbers
- Trastuzumab Deruxtecan in Elderly Patients and Those With Other Illnesses
- Trastuzumab Deruxtecan vs T-DM1 and Trastuzumab: How ADCs Differ
- When Trastuzumab Deruxtecan Stops Working: Resistance and What Comes Next
- Where Trastuzumab Deruxtecan Fits Alongside Chemotherapy and Hormone Therapy
- Who Is Eligible for Trastuzumab Deruxtecan? HER2-Positive and HER2-Low Breast, Gastric and Lung Cancer
- Will Insurance or a Government Scheme Pay for Trastuzumab Deruxtecan?
- Work, Travel and Daily Life on Trastuzumab Deruxtecan
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Can trastuzumab be given for longer than one year in early breast cancer?
One year remains the standard duration recommended by NCCN, ASCO and ESMO for early-stage HER2-positive breast cancer. Some trials have looked at extending or shortening this period, and the evidence so far does not support routinely going beyond one year for most patients. If your oncologist is recommending a different duration, ask which guideline or trial that is based on and what the expected benefit is for your situation.
What if I miss an infusion or my appointment is delayed?
A short delay — missing a session by a week or two because of illness or scheduling — rarely changes outcomes significantly. Your team will advise on whether to continue the original schedule or adjust the remaining doses. Do not skip an infusion without telling your team, because the reason for the gap affects what they decide to do next.
Does trastuzumab ever stop working in advanced cancer?
Yes. In metastatic disease, most patients eventually develop resistance — trastuzumab stops controlling the cancer after a period that varies from person to person. When that happens, your oncologist will discuss switching to a different HER2-targeted agent. Several effective options exist for second and later lines of treatment, so resistance to trastuzumab is not the end of HER2-directed therapy.
My heart result dropped during treatment. Does that mean I cannot finish the course?
Not necessarily. A drop in LVEF during trastuzumab is one of the more common reasons treatment is paused, and many patients restart successfully once heart function recovers. Whether you can restart, and how long a pause is needed, depends on how much the reading dropped and whether it recovers. Your oncologist will guide that decision. It is worth asking what the target recovery level looks like so you are not waiting without a clear benchmark.
I finished my one-year course two months ago. Do I still need heart monitoring?
Your team will typically schedule at least one post-treatment heart check, usually a few months after your final infusion. After that, ongoing monitoring depends on your individual risk factors and whether your LVEF was affected during treatment. If you notice any cardiac symptoms after finishing — breathlessness, ankle swelling, palpitations — report them to your team rather than assuming they are unrelated.
Can I have trastuzumab if I am thinking about becoming pregnant?
Trastuzumab is not recommended during pregnancy because of the risk of harm to the developing baby, particularly to kidney development. If you are of reproductive age, this is a conversation to have with your oncologist before or early in treatment — not after. Your team can advise on timing relative to family planning and refer you to a fertility specialist if needed. Do not stop treatment without telling your team first.